Elotuzumab is a monoclonal antibody used in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. It targets the SLAMF7 (Signaling Lymphocytic Activation Molecule Family member 7) protein found on the surface of myeloma cells and natural killer cells. Elotuzumab is typically used in combination with other drugs, such as lenalidomide and dexamethasone, to increase its effectiveness. It is administered via intravenous infusion and is used in patients who have received prior therapies for multiple myeloma.